Initial Effort to Elucidate the Role of Plasma Gelsolin in Human Diseases with Significant Inflammatory and Infectious Disease Complications

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2014) BioAegis Therapeutics has announced that it has entered into a research collaboration with the National Institute of Allergy and Infectious Diseases. NIAID, which is one of the 27 research centers that make up the National Institute of Health, conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. This research collaboration will investigate an undisclosed orphan indication, as well as further elucidate the function of plasma gelsolin in immune cells.